Lupin Limited has moved closer to the United States enzalutamide market with proposed 120 mg and 160 mg tablets that could reduce pill burden. Patent timing, final approval, market access and competition will determine whether that formulation advantage becomes commercially meaningful.
Find out how Saptalis Pharmaceuticals’ cyclosporine launch could reshape access, competition and generic dry eye treatment.
Find out how Concord Biotech’s FDA approval for Mycophenolate Mofetil could reshape its transplant generics strategy.
Lupin Limited has launched generic dapagliflozin in the United States. Read what it means for Farxiga, pricing pressure, and market access.
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
Lupin Limited has won tentative FDA approval for pitolisant tablets. Read why timing, exclusivity, and Wakix market dynamics matter next.